114 related articles for article (PubMed ID: 25038068)
1. HIV-1 DNA concentrations and evolution among African HIV-1-infected children under antiretroviral treatment (ANRS 1244/1278).
Boullé C; Rouet F; Fassinou P; Msellati P; Debeaudrap P; Chaix ML; Rouzioux C; Avettand-Fenoel V
J Antimicrob Chemother; 2014 Nov; 69(11):3047-50. PubMed ID: 25038068
[TBL] [Abstract][Full Text] [Related]
2. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
[TBL] [Abstract][Full Text] [Related]
3. Morbidity in HIV-1-Infected children treated or not treated with highly active antiretroviral therapy (HAART), Abidjan, Cote d'Ivoire, 2000-04.
Walenda C; Kouakoussui A; Rouet F; Wemin L; Anaky MF; Msellati P
J Trop Pediatr; 2009 Jun; 55(3):170-6. PubMed ID: 19066169
[TBL] [Abstract][Full Text] [Related]
4. Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens.
Rouet F; Fassinou P; Inwoley A; Anaky MF; Kouakoussui A; Rouzioux C; Blanche S; Msellati P;
AIDS; 2006 Nov; 20(18):2315-9. PubMed ID: 17117017
[TBL] [Abstract][Full Text] [Related]
5. Virologic and immunologic response to antiretroviral therapy and predictors of HIV type 1 drug resistance in children receiving treatment in Abidjan, Côte d'Ivoire.
Adjé-Touré C; Hanson DL; Talla-Nzussouo N; Borget MY; Kouadio LY; Tossou O; Fassinou P; Bissagnene E; Kadio A; Nolan ML; Nkengasong JN
AIDS Res Hum Retroviruses; 2008 Jul; 24(7):911-7. PubMed ID: 18593341
[TBL] [Abstract][Full Text] [Related]
6. Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Côte d'Ivoire.
Seyler C; Anglaret X; Dakoury-Dogbo N; Messou E; Touré S; Danel C; Diakité N; Daudié A; Inwoley A; Maurice C; Tonwe-Gold B; Rouet F; N'Dri-Yoman T; Salamon R;
Antivir Ther; 2003 Oct; 8(5):385-93. PubMed ID: 14640385
[TBL] [Abstract][Full Text] [Related]
7. Frequent occurrence of chronic hepatitis B virus infection among West African HIV type-1-infected children.
Rouet F; Chaix ML; Inwoley A; Anaky MF; Fassinou P; Kpozehouen A; Rouzioux C; Blanche S; Msellati P;
Clin Infect Dis; 2008 Feb; 46(3):361-6. PubMed ID: 18171303
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of dried blood spot diagnosis using HIV1-DNA and HIV1-RNA Biocentric assays in infants in Abidjan, Côte d'Ivoire. The Pedi-Test DBS ANRS 12183 Study.
Yapo V; d'Aquin Toni Td; Desmonde S; Amani-Bosse C; Oga M; Lenaud S; Menan H; Timité-Konan M; Leroy V; Rouzioux C
J Virol Methods; 2013 Nov; 193(2):439-45. PubMed ID: 23872283
[TBL] [Abstract][Full Text] [Related]
9. Relationships between HIV disease history and blood HIV-1 DNA load in perinatally infected adolescents and young adults: the ANRS-EP38-IMMIP study.
Avettand-Fenoel V; Blanche S; Le Chenadec J; Scott-Algara D; Dollfus C; Viard JP; Bouallag N; Benmebarek Y; Rivière Y; Warszawski J; Rouzioux C; Buseyne F
J Infect Dis; 2012 May; 205(10):1520-8. PubMed ID: 22427678
[TBL] [Abstract][Full Text] [Related]
10. A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir.
Piketty C; Weiss L; Assoumou L; Burgard M; Mélard A; Ragnaud JM; Bentata M; Girard PM; Rouzioux C; Costagliola D;
J Med Virol; 2010 Nov; 82(11):1819-28. PubMed ID: 20872707
[TBL] [Abstract][Full Text] [Related]
11. HIV type 1 drug resistance in adults receiving highly active antiretroviral therapy in Abidjan, Côte d'Ivoire.
Hanson DL; Adjé-Touré C; Talla-Nzussouo N; Eby P; Borget MY; Kouadio LY; Celestin BE; Tossou O; Eholie S; Kadio A; Chorba T; Nkengasong JN
AIDS Res Hum Retroviruses; 2009 May; 25(5):489-95. PubMed ID: 19388820
[TBL] [Abstract][Full Text] [Related]
12. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts.
Hocqueloux L; Avettand-Fènoël V; Jacquot S; Prazuck T; Legac E; Mélard A; Niang M; Mille C; Le Moal G; Viard JP; Rouzioux C;
J Antimicrob Chemother; 2013 May; 68(5):1169-78. PubMed ID: 23335199
[TBL] [Abstract][Full Text] [Related]
13. CD4+ T Cell Recovery and Hepatitis B Virus Coinfection in HIV-Infected Patients from Côte d'Ivoire Initiating Antiretroviral Therapy.
Houghtaling L; Moh R; Abdou Chekaraou M; Gabillard D; Anglaret X; Eholié SP; Zoulim F; Danel C; Lacombe K; Boyd A
AIDS Res Hum Retroviruses; 2018 May; 34(5):439-445. PubMed ID: 29466862
[TBL] [Abstract][Full Text] [Related]
14. Quantification of HIV-1 p24 by a highly improved ELISA: an alternative to HIV-1 RNA based treatment monitoring in patients from Abidjan, Côte d'Ivoire.
Tehe A; Maurice C; Hanson DL; Borget MY; Abiola N; Maran M; Yavo D; Tomasik Z; Böni J; Schüpbach J; Nkengasong JN
J Clin Virol; 2006 Nov; 37(3):199-205. PubMed ID: 16973409
[TBL] [Abstract][Full Text] [Related]
15. Cellular HIV-1 DNA quantification and short-term and long-term response to antiretroviral therapy.
Masquelier B; Taieb A; Reigadas S; Marchou B; Cheneau C; Spire B; Charpentier C; Leport C; Raffi F; Chêne G; Descamps D;
J Antimicrob Chemother; 2011 Jul; 66(7):1582-9. PubMed ID: 21525020
[TBL] [Abstract][Full Text] [Related]
16. Temporal trends in mortality and loss to follow-up among children enrolled in Côte d'Ivoire's national antiretroviral therapy program.
Auld AF; Tuho MZ; Ekra KA; Shiraishi RW; Mohamed F; Kouakou JS; Ettiègne-Traoré V; Sabatier J; Essombo J; Rivadeneira ED; Adjorlolo-Johnson G; Marlink R; Ellerbrock TV
Pediatr Infect Dis J; 2014 Nov; 33(11):1134-40. PubMed ID: 25093975
[TBL] [Abstract][Full Text] [Related]
17. Impact of the Timing of Initiation of Antiretroviral Therapy During Primary HIV-1 Infection on the Decay of Cell-Associated HIV-DNA.
Laanani M; Ghosn J; Essat A; Melard A; Seng R; Gousset M; Panjo H; Mortier E; Girard PM; Goujard C; Meyer L; Rouzioux C;
Clin Infect Dis; 2015 Jun; 60(11):1715-21. PubMed ID: 25737374
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report.
Frange P; Faye A; Avettand-Fenoël V; Bellaton E; Descamps D; Angin M; David A; Caillat-Zucman S; Peytavin G; Dollfus C; Le Chenadec J; Warszawski J; Rouzioux C; Sáez-Cirión A;
Lancet HIV; 2016 Jan; 3(1):e49-54. PubMed ID: 26762993
[TBL] [Abstract][Full Text] [Related]
19. Pediatric viral human immunodeficiency virus type 1 RNA levels, timing of infection, and disease progression in African HIV-1-infected children.
Rouet F; Sakarovitch C; Msellati P; Elenga N; Montcho C; Viho I; Blanche S; Rouzioux C; Dabis F; Leroy V;
Pediatrics; 2003 Oct; 112(4):e289. PubMed ID: 14523214
[TBL] [Abstract][Full Text] [Related]
20. Evolution of lipid levels in HIV-infected children treated or not with HAART in Abidjan, Cote d'Ivoire.
Cournil A; Mercier-Deheuvels S; Dupuy AM; Cristol JP; Anaky MF; Rouet F; Fassinou P; Msellati P
J Trop Pediatr; 2012 Feb; 58(1):43-9. PubMed ID: 21558308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
